Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases to the brain. The study will have three phases, Phase 1, Phase 2a and Phase 2b.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Zdiagnozowany nowotwór mózgu lub przerzuty do mózgu potwierdzone badaniem obrazowym
- •Oczekiwana długość życia co najmniej 3 miesiące
- •Dobry ogólny stan zdrowia (wynik funkcjonowania co najmniej 60%)
- •Badanie MRI mózgu wykonane w ciągu 14 dni przed rozpoczęciem leczenia
- •Prawidłowe wyniki badań krwi (liczba płytek, białe krwinki, funkcja nerek i wątroby)
- •Jeśli pacjent ma napady padaczki, muszą być one kontrolowane przez 14 dni przed badaniem
- •Gotowość do stosowania antykoncepcji przez czas trwania badania
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (7)
Precision NextGen Oncology
Beverly Hills, United States
OPN Healthcare, Inc
Glendale, United States
University of Southern California
Los Angeles, United States
MDR Core Network
Boynton Beach, United States
Vanderbilt University Medical Center
Nashville, United States
Baylor, Scott and White Research Institute
Dallas, United States
Northwest Medical Specialties
Tacoma, United States
Trial contact
Christopher Beardmore
Chloe Richmond
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.